New Outlook For NEO, Busy Days Ahead For OASM, OPK's Rayaldee Gets 2nd Chance

The New Drug Application for RAYALDEE, resubmitted by OPKO Health Inc. (OPK), has been accepted for review by the FDA, and a decision is scheduled for October 22, 2016.

from RTT - Biotech http://ift.tt/26wflKU
via IFTTT